Advances in the pharmacological management of neutropenia in solid tumors: the advent of biosimilars

References

• Atkinson TM, Ryan SJ, Bennett AV, et al. The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review. Support Care Cancer. 2016;24(8):3669–3676.
   PubMed Web of Science ®Google Scholar
• Klastersky J, de Naurois J, Rolston K, et al. ESMO Guidelines Committee. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016;27:111–118.
   PubMed Web of Science ®Google Scholar
• Mehta H, Malandra M, Corey S. G-CSF and GM-CSF in neutropenia. J Immunol. 2015;195:1341–1349.
   PubMed Web of Science ®Google Scholar
• Gladkov O, Moiseyenko V, Bondarenko IN, et al. Phase II dose-finding study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy. Med Oncol. 2015;32:623.
   PubMed Web of Science ®Google Scholar
• Fukunaga R, Ishizaka-Ikeda E, Seto Y, et al. Expression cloning of a receptor for murine granulocyte colony-stimulating factor. Cell. 1990;61:341–350.
   PubMed Web of Science ®Google Scholar
• Ghidini M, Hahne JC, Trevisani F, et al. New developments in the treatment of chemotherapy-induced neutropenia: focus on balugrastim. Ther Clin Risk Manag. 2016;12:1009–1015.
   PubMed Web of Science ®Google Scholar
• Schroder CP, de Vries EG, Mulder NH, et al. Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B. J Antimicrob Chemother. 1999;43:741–743.
   PubMed Web of Science ®Google Scholar
• Smith TL, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: american Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015;33:3199–3212.
   PubMed Web of Science ®Google Scholar
• Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer. 2006;42:2433–2453.
   PubMed Web of Science ®Google Scholar
• Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47:8–32.
   PubMed Web of Science ®Google Scholar
• Becker PS, Griffiths EA, Alwan LM, et al. NCCN Guidelines Insights: hematopoietic Growth Factors, Version 1. J Natl Compr Canc Netw. 2020;18:12–22. 2020
   PubMed Web of Science ®Google Scholar
• Crawford J, Caserta C, Roila F, et al. Hematopoietic growth factors: ESMO clinical practice guidelines for the applications. Ann Oncol. 2010;21:248–251.
   PubMed Web of Science ®Google Scholar
• Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropenia: ESMO clinical practice guideline. Ann Oncol. 2016;27(suppl5):111–118.
   Google Scholar
• Ratti M, Tomasello G. Lipegfilgrastim for the prophylaxis and treatment of chemotherapy-induced neutropenia. Expert Rev Clin Pharmacol. 2015;8:15–24.
   PubMed Web of Science ®Google Scholar
• Ria R, Gasparre T, Mangialardi G, et al. Comparison between filgrastim and lenograstim plus chemotherapy for mobilization of PBPCs. Bone Marrow Transplant. 2010;45:277–281.
   PubMed Web of Science ®Google Scholar
• Pfeil AM, Allcott K, Pettengell R, et al. Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review. Support Care Cancer. 2015;23:525–545.
   PubMed Web of Science ®Google Scholar
• Guideline on similar biological medicinal products containing recombinant granulocyte-colony stimulating factor (rG-CSF), EMEA/CHMP/BMWP/31329/2005 Rev 1, 2018. Available at: http://www.ema.europa.eu [Last accessed 2020 May 17th
   Google Scholar
• GH DDC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol. 2003;21:4524–4531.
   PubMed Web of Science ®Google Scholar
• Patel D, Gillis C, Naggar J, et al. The rise of biosimilars: how they got there and where they are going. Metabolism. 2017;75:45–53.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Kuderer N, Greene J, et al. The economics of febrile neutropenia: implications for the use of colony- stimulating factors. Eur J Cancer. 1998;34:1857–1864.
   PubMed Web of Science ®Google Scholar
• Webster J, Lyman GH. Use of G-CSF to sustain dose intensity in breast cancer patients receiving adjuvant chemotherapy: a pilot study. Cancer Control. 1996;3:519–523.
   PubMedGoogle Scholar
• Aapro MS, Bohlius J, Cameron DA, et al. 2010 Update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47:8–32.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Khatcheressian J, Lyman GH, et al. update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24:3187–3205. 2006. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103353s5184lbl.pdf
   PubMed Web of Science ®Google Scholar
• Sung L, Nathan PC, Alibhai SM, et al. Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infections. Ann Intern Med. 2007;147:400–411.
   PubMed Web of Science ®Google Scholar
• Welte K. G-CSF: filgrastim, lenograstim and biosimilars. Expert Opin Biol Ther. 2014;14:983–993.
   PubMed Web of Science ®Google Scholar
• Yang BB, Savin MA, Green M. Prevention of chemotherapy-induced neutropenia with pegfilgrastim: pharmacokinetics and patient outcomes. Chemotherapy. 2012;58:387–398.
   PubMed Web of Science ®Google Scholar
• Bennett CL, Djulbegovic B, Norris LB, et al. Colony-stimulating factors for febrile neutropenia during cancer therapy. N Engl J Med. 2013;368:1131–1139.
   PubMed Web of Science ®Google Scholar
• Neupogen ® (filgrastim) [prescribing information]. Thousand Oaks, CA: Amgen Inc; 2012.
   Google Scholar
• Neulasta ® (pegfilgrastim) [prescribing information]. Thousand Oaks, CA: Amgen Inc; 2012. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125031s180lbl.pdf
   Google Scholar
• Clark OA, Lyman GH, Castro AA, et al. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol. 2005;23:4198–4214.
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Dale DC, Crawford J, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25:3158–3167.
   PubMed Web of Science ®Google Scholar
• Cooper KL, Madan J, Whyte S, et al. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer. 2011;11:404.
   PubMed Web of Science ®Google Scholar
• Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small- cell lung cancer. N Engl J Med. 1991;325:164–170.
   PubMed Web of Science ®Google Scholar
• Heil G, Hoelzer D, Sanz MA, et al. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood. 1997;90:4710–4718.
   PubMed Web of Science ®Google Scholar
• Clemons M, Fergusson D, Simos D, et al. A multicentre, randomized trial comparing schedules of G-CSF (filgrastim) administration for primary prophylaxis of chemotherapy-induced febrile neutropenia in early stage breast cancer. Annals Oncol. 2020;31:951–957.
   PubMed Web of Science ®Google Scholar
• Pinto L, Liu Z, Doan Q, et al. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr Med Res Opin. 2007;23:2283–2295.
   PubMed Web of Science ®Google Scholar
• Holmes FA, Jones SE, O’Shaughnessy J, et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol. 2002;13:903–909.
   PubMed Web of Science ®Google Scholar
• Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2003;14:29–35.
   PubMed Web of Science ®Google Scholar
• Naeim A, Henk HJ, Becker L, et al. Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF). BMC Cancer. 2013;13:11.
   PubMed Web of Science ®Google Scholar
• George S, Yunus F, Case D, et al. Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin’s lymphoma. Leuk Lymphoma. 2003;44:1691–1696.
   PubMed Web of Science ®Google Scholar
• Brusamolino E, Rusconi C, Montalbetti L, et al. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. Haematologica. 2006;91:496–502.
   PubMed Web of Science ®Google Scholar
• Neulasta® (pegfilgrastim) Onpro® kit. [Healthcare Provider Instructions for Use]. Thousand Oaks, CA: Amgen Inc; 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125031s189s191lbl.pdf
   Google Scholar
• European Medicines Agency. Granocyte® (lenograstim): EU summary of product characteristics. Chugai Pharmaceutical Co.; 2009. https://www.medicines.org.uk/emc/product/1577/smpc#gref
   Google Scholar
• Holloway CJ. Applications of recombinant DNA technology in the production of glycosylated recombinant human granulocyte colony stimulating factor. Eur J Cancer. 1994;30A:2–6.
   PubMed Web of Science ®Google Scholar
• Chamorey AL, Magne N, Pivot X. Impact of glycosylation on the effect of cytokines. A special focus on oncology. Eur Cytokine Netw. 2012;13:154–160.
   Google Scholar
• Swanson G, Bergstrom K, Stump E, et al. Growth factor usage patterns and outcomes in the community setting: collection through a practice-based computerized clinical information system. J Clin Oncol. 2000;18:1764–1770.
   PubMed Web of Science ®Google Scholar
• Falandry C, Campone M, Cartron G, et al. Trends in G-CSF use in 990 patients after EORTC and ASCO guidelines. Eur J Cancer. 2010;46:2389–2398.
   PubMed Web of Science ®Google Scholar
• Sourgens H, Lefrere F. A systematic review of available clinical evidence – filgrastim compared with lenograstim. Int J Clin Pharmacol Ther. 2011;49:510–518.
   PubMed Web of Science ®Google Scholar
• Lonquex ®. Summary of Product Characteristics. London: European Medicines Agency; 2013.
   Google Scholar
• Bondarenko I, Gladkov OA, Elsaesser R, et al. Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy. BMC Cancer. 2013;13:386.
   PubMed Web of Science ®Google Scholar
• Gladkov OA, Buchner A, Bias P, et al. Chemotherapy- associated treatment burden in breast cancer patients receiving lipegfilgrastim or pegfilgrastim: secondary efficacy data from a phase III study. Support Care Cancer. 2016;24:395–400.
   PubMed Web of Science ®Google Scholar
• Bondarenko IM. Bias P and Buchner A. Incidence of bone pain in patients with breast cancer treated with lipegfilgrastim or pegfilgrastim: an integrated analysis from phase II and III studies. Support Care Cancer. 2016;24:267–273.
   PubMed Web of Science ®Google Scholar
• Gladkov O, Moiseyenko V, Bondarenko IN, et al. Phase II dose-finding study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy. Med Oncol. 2015;32:623.
   PubMed Web of Science ®Google Scholar
• Gladkov O, Moiseyenko V, Bondarenko IN, et al. A phase III study of balugrastim versus pegfilgrastim in breast cancer patients receiving chemotherapy with doxorubicin and docetaxel. Oncologist. 2016;21:7–15.
   PubMed Web of Science ®Google Scholar
• Volovat C, Gladkov OA, Bondarenko IM, et al. Efficacy and safety of balugrastim compared with pegfilgrastim in patients with breast cancer receiving chemotherapy. Clin Breast Cancer. 2014;14:101–108.
   PubMed Web of Science ®Google Scholar
• Engranli: withdrawal of the marketing authorisation application. Available at: http://www.ema.europa.eu. [Last accessed 2020 Oct 7th]
   Google Scholar
• Roth K, Lehnick D, Wessels H, et al. Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Pelmeg®, a pegfilgrastim biosimilar in healthy subjects. Pharmacol Res Perspect. 2019;7:e00503.
   PubMed Web of Science ®Google Scholar
• Sorgel F, Schwebig A, Holzmann J, et al. Comparability of biosimilar filgrastim with originator filgrastim: protein characterization, pharmacodynamics, and pharmacokinetics. Biodrugs. 2015;29:123–131.
   PubMed Web of Science ®Google Scholar
• Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov. 2003;2:214–221.
   PubMed Web of Science ®Google Scholar
• Zündorf I, Dingermann T. PEGylation – a well-proven strategy for the improvement of recombinant drugs. Pharmazie. 2014;69:323–326.
   PubMed Web of Science ®Google Scholar
• Veronese FM, Mero A. The impact of PEGylation on biological therapies. Biodrugs. 2008;22:315–329.
   PubMed Web of Science ®Google Scholar
• Choi C, Yoo BW, Kim CO, et al. Comparison of biosimilar filgrastim with a reference product: pharmacokinetics, pharmacodynamics, and safety profiles in healthy volunteers. Drug Des Devel Ther. 2018;12:2381–2387.
   PubMed Web of Science ®Google Scholar
• Willis F, Pettengell R. Pegfilgrastim. Expert Opin Biol Ther. 2002;2:985–992.
   PubMed Web of Science ®Google Scholar
• Yang BB, Kido A. Pharmacokinetics and pharmacodynamics of pegfilgrastim. Clin Pharmacokinet. 2011;50:295–306.
   PubMed Web of Science ®Google Scholar
• Zamboni WC. Pharmacokinetics of pegfilgrastim. Pharmacotherapy. 2003;23:9–14.
   PubMed Web of Science ®Google Scholar
• Höglund M. Glycosylated and non-glycosylated recombinant human granulocyte colony-stimulating factor (rhG-CSF)–what is the difference? Med Oncol. 1998;15:229–233.
   PubMed Web of Science ®Google Scholar
• Ribeiro D, Veldwijk MR, Benner A, et al. Differences in functional activity and antigen expression of granulocytes primed in vivo with filgrastim, lenograstim, or pegfilgrastim. Transfusion. 2007;47:969–980.
   PubMed Web of Science ®Google Scholar
• Ataergin S, Arpaci F, Turan M, et al. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation. Am J Hematol. 2008;83(8):644–648.
   PubMed Web of Science ®Google Scholar
• Orciuolo E, Buda G, Marturano E, et al. Lenograstim reduces the incidence of febrile episodes, when compared with filgrastim, in multiple myeloma patients undergoing stem cell mobilization. Leuk Res. 2011;35:899–903.
   PubMed Web of Science ®Google Scholar
• Ria R, Gasparre T, Mangialardi G, et al. Comparison between filgrastim and lenograstim plus chemotherapy for mobilization of PBPCs. Bone Marrow Transplant. 2010;45:277–281.
   PubMed Web of Science ®Google Scholar
• Ria R, Reale A, Melaccio A, et al. Filgrastim, lenograstim and pegfilgrastim in the mobilization of peripheral blood progenitor cells in patients with lymphoproliferative malignancies. Clin Exp Med. 2015;15:145–150.
   PubMed Web of Science ®Google Scholar
• Sourgens H, Lefrère F. A systematic review of available clinical evidence - filgrastim compared with lenograstim. Int J Clin Pharmacol Ther. 2011;49:510–518.
   PubMed Web of Science ®Google Scholar
• Mahlert F, Schmidt K, Allgaier H, et al. Rational development of lipegfilgrastim, a novel long-acting granulocyte colony-stimulating factor, using glycopegylation technology. Blood. 2013;122(21):4853.
   Web of Science ®Google Scholar
• Scheckermann C, Schmidt K, Abdolzade-Bavil A, et al. Lipegfilgrastim: a long-acting, once-per-cycle, glycopegylated recombinant human filgrastim. J Clin Oncol. 2013;31(Suppl15):e13548.
   Web of Science ®Google Scholar
• Bond TC, Szabo E, Gabriel S, et al. Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events. J Oncol Pharm Pract. 2018;24:412–423.
   PubMed Web of Science ®Google Scholar
• Abdolzade-Bavil A, Cooksey BA, Scheckermann C, et al. Pegylated versus glycopegylated G-CSFs and their biochemical and physiological properties. Blood. 2013;122:4851.
   Web of Science ®Google Scholar
• Abdolzade-Bavil A, von Kerczek A, Cooksey BA, et al. Differential sensitivity of lipegfilgrastim and pegfilgrastim to neutrophil elastase correlates with differences in clinical pharmacokinetic profile. J Clin Pharmacol. 2016;56:186–194.
   PubMed Web of Science ®Google Scholar
• Dale DC, Crawford J, Klippel Z, et al. A systematic literature review of the efficacy, effectiveness, and safety of filgrastim. Support Care Cancer. 2018;26:7–20.
   PubMed Web of Science ®Google Scholar
• Tholpady A, Chiosea I, Lyons JJ, et al. Systemic hypersensitivity reaction mimicking anaphylaxis after first filgrastim administration in a healthy donor. Transfusion. 2013;53(5):1146–1147.
   PubMed Web of Science ®Google Scholar
• Akyol G, Pala C, Yildirim A, et al. A rare but sever complication of filgrastim in a healthy donor: splenic rupture. Transfus Apher Sci. 2014;50:53–55.
   PubMed Web of Science ®Google Scholar
• Martin WG, Ristow KM, Habermann TM, et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s lymphoma. J Clin Oncol. 2005;23:7614–7620.
   PubMed Web of Science ®Google Scholar
• Herrman F, Shulz G, Lindermann A, et al. Yeast-expressed granulocyte-macrophage colony-stimulating factor in cancer patients: aphase Ib clinical study. In: Behring Inst Mitt. 1988. p. 107–118. https://pubmed.ncbi.nlm.nih.gov/2467645/
   Google Scholar
• .U.S. Food and Drug Administration. Sargramostim label information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103362s5240lbl.pdf. [Last accessed 2020 May 17th]
   Google Scholar
• Jeong GH, Lee KH, Lee IR, et al. Incidence of Capillary Leak Syndrome as an Adverse Effect of Drugs in Cancer Patients: A Systematic Review and Meta-analysis. J Clin Med. 2019;8:E143.
   PubMed Web of Science ®Google Scholar
• Hadji P, Kostev K, Schroder-Bernhardi D, et al. Cost comparison of outpatient treatment with granulocyte colony-stimulating factors (G-CSF) in Germany. Int J Clin Pharmacol Ther. 2012;50:281–289.
   PubMed Web of Science ®Google Scholar
• Guideline on similar biological medicinal products containing recombinant granulocyte-colony stimulating factor (rG-CSF), EMEA/CHMP/BMWP/31329/2005 Rev 1. (2018). Available at: http://www.ema.europa.eu. [Last accessed 2020 May 17th]
   Google Scholar
• Wolff-Holz E, Tiitso K, Vleminckx C, et al. Evolution of the AU Biosimilar Framework: past and Future. BioDrugs. 2019;33:621–634.
   PubMed Web of Science ®Google Scholar
• Derbyshire M. Patent expiry dates for biologicals: 2018 update. GaBI J. 2019;8:24–31.
   Google Scholar
• Biosimilar G-CSF prescribed more than originator. Mol, Belgium: pro Pharma Communications International. Available at: www.gabionline.net/Biosimilars/News/Biosimilar-G-CSF-prescribed-more-than-originator. [Last accessed 2020 May 17th]
   Google Scholar
• Blackwell K, Gascon P, Krendyukov A, et al. Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase 3, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive therapy. Ann Oncol. 2018;29:244–249.
   PubMed Web of Science ®Google Scholar
• Harbeck N, Gascon P, Krendyukov A, et al. Safety profile of biosimilar filgrastim (Zarzio/Zarxio): a combined analysis of phase III studies. Oncologist. 2018;23:403–409.
   PubMed Web of Science ®Google Scholar
• Zecchini J, Yum K, Steinberg A, et al. A single-center, retrospective analysis to compare the efficacy and safety of filgrastim-sndz to filgrastim for prophylaxis of chemotherapy-induced neutropenia and for neutrophil recovery during following autologous stem cell transplantation. Support Care Cancer. 2017;26:1013–1016.
   PubMed Web of Science ®Google Scholar
• Chen X, Agiro A, Barron J, et al. Early adoption of biosimilar growth factor in supportive cancer care. JAMA Oncol. 2018;4:1779–1781.
   PubMed Web of Science ®Google Scholar
• .Waller CF, Semiglazov VF, Tjulandin S, et al. A phase III randomized equivalence study of biosimilar filgrastim versus Amgen filgrastim in patients receiving myelosuppressive chemotherapy for breast cancer. Onkologie. 2010;33:504–511.
   PubMedGoogle Scholar
• Fruehauf S, Otremba B, Stotzer O, et al. Compatibility of biosimilar filgrastim with cytotoxic chemotherapy during the treatment of malignant diseases (VENICE): a prospective, multicenter, non-interventional, longitudinal study. Adv Ther. 2016;33:1983–2000.
   PubMed Web of Science ®Google Scholar
• Brito M, Esteves S, Andre R, et al. Comparison of effectiveness of biosimilar filgrastim (Nivestim) reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with (neo)adjuvant TAC: a non-interventional cohort study. Support Care Cancer. 2016;24:597–603.
   PubMed Web of Science ®Google Scholar
• Frederic M, Stephane L, Didier K, et al. Biosimilar filgrastim in the treatment and the prevention of chemotherapy-induced neutropenia: the next study. J Geriatr Oncol. 2014;5:S71.
   PubMedGoogle Scholar
• Waller CF, Tiessen RG, Lawrence TE, et al. A pharmacokinetics and pharmacodynamics equivalence trial of the proposed pegfilgrastim biosimilar, MYL-1401H, versus reference pegfilgrastim. J Cancer Res Clin Oncol. 2018;144:1087–1095.
   PubMed Web of Science ®Google Scholar
• Waller CF, Ranganna GM, Pennella EJ, et al. Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia. Ann Hematol. 2019;98:1217–1224.
   PubMed Web of Science ®Google Scholar
• Waller CF, Ranganna GM, Pennella EJ, et al. Comparison of immunogenicity between the proposed pegfilgrastim biosimilar MYL-1401H and reference pegfilgrastim. Blood. 2017;130:3568.
   Web of Science ®Google Scholar
• Glaspy JA, O’Connor PG, Tang H, et al. Randomized, single-blind, crossover study to assess the pharmacokinetic and pharmacodynamic bioequivalence of CHS-1701 to pegfilgrastim in healthy subjects. J Clin Oncol. 2017;35:e21693.
   Web of Science ®Google Scholar
• Harbeck N, Lipatov O, Frolova M, et al. Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer. Future Oncol. 2016;12:1359–1367.
   PubMed Web of Science ®Google Scholar
• Blackwell K, Donskih R, Jones CM, et al. A comparison of proposed biosimilar LA-EP2006 and reference pegfilgrastim for the prevention of neutropenia in patients with early-stage breast cancer receiving myelosuppressive adjuvant or neoadjuvant chemotherapy: pegfilgrastim randomized oncology (supportive care) trial to evaluate comparative treatment (PROTECT-2), a phase III, randomized, double-blind trial. Oncologist. 2016;21:789–794.
   PubMed Web of Science ®Google Scholar
• Möbus V, Jackisch C, Lück HJ, et al. Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial. Ann Oncol. 2018;29:178–185.
   PubMed Web of Science ®Google Scholar